Overview
Omnicell Q3 2025 revenue grows 10% yr/yr, driven by connected devices and services
Adjusted EPS for Q3 2025 beats analyst expectations
Company repurchased 1.987 mln shares, repaid $175 mln convertible senior notes
Outlook
Omnicell raises 2025 total revenue guidance to $1.177 bln - $1.187 bln
Company expects Q4 2025 revenue between $306 mln and $316 mln
Omnicell projects full-year 2025 non-GAAP EPS of $1.63 - $1.73
Result Drivers
CONNECTED DEVICES - Omnicell's flagship point-of-care connected devices were a core driver of revenue growth
TECHNICAL SERVICES - Growth in technical services offerings contributed to increased revenues
CONSUMABLES AND SAAS - Increases in consumables and SaaS and Expert Services revenues supported revenue growth
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | $311 mln | ||
Q3 Adjusted EPS | Beat | $0.51 | $0.36 (8 Analysts) |
Q3 Adjusted Net Income | $24 mln | ||
Q3 Net Income | $5 mln | ||
Q3 Adjusted EBITDA | $41 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Omnicell Inc is $41.00, about 27.9% above its October 29 closing price of $29.57
The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 21 three months ago
Press Release: ID:nBw4ztyb0a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments